Manufacturing and Production

Showing 15 posts of 5866 posts found.

tablet_production_2

British Biosimilars Association launches in UK

April 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Napp, bba, bgma, british biosimilars association

A new industry body, the British Biosimilars Association, has been formally launched today with the sole focus of increasing the …
stocks1

Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…

April 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market

Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …
shire_image

Shire announces new $400 million biologics plant and 400 new jobs in Ireland

April 18, 2016 Manufacturing and Production, Sales and Marketing IDA, Ireland, Shire, investment, meath, shire pharmaceuticals

Shire Pharmaceuticals has announced the expansion of its Irish operations with a new $400 million biologics plant set to deliver …
astrazeneca_building_white

AstraZeneca hold internal talks for Medivation takeover – reports

April 18, 2016 Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover

AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …
clinical_trial_4

Synta Pharmaceuticals announces merger with Madrigal

April 15, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger

Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …
abbvie_0

AbbVie announces positive Phase III results in hepatitis C drug

April 14, 2016 Manufacturing and Production, Research and Development AbbVie, hepatitis, phase III

AbbVie (NYSE: ABBV) has announced positive results from their Phase III evaluating the combination of Viekirax and Exviera, with or …
sanofi_hq__boetie_hall

Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office

April 13, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, Stevenage Bioscience Catalyst, academia, industry, partnership, pharma, stevenage

Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new partnering office. This office will …
opdivo_1

Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU

April 13, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo

Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …
chemo-web

EUSA Pharma acquires global rights to oncology support drug

April 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Eusa Pharma, acroral, acroral tab, global rights, oncology

EUSA Pharma has announced the acquisition of global rights to oncology support care product, Arcoral Tab, from Arcoral Pharma.
regeneron

Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology

April 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics

Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …
dollars_medicines

KaloBios announces new affordable pricing model, refuses to engage in “price gouging”

April 12, 2016 Manufacturing and Production, Sales and Marketing CEO, Drug pricing, KaloBios, Martin Shkreli, Shkreli, affordable, price gouging, price model, responsible

Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …
astrazeneca_sign_sky

Clinical studies point to consistent efficacy in AstraZeneca’s treatment for drug-resistance bacteria

April 12, 2016 Manufacturing and Production, Research and Development AstraZeneca, avibactam, ceftazidime, gram resistant

AstraZeneca has presented results from a series of trials which show the consistent efficacy of investigational antibiotic, ceftazidime-avibactam (CAZ-AVI) in …
roche

Roche’s Venclexta gets accelerated approval from US FDA for chronic lymphocytic leukemia

April 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Roche, US FDA, Venclexta, chronic lymphocytic leukemia

Swiss drug firm Roche (SIX: ROG) on Tuesday said the US Food and Drug Administration (FDA) has granted accelerated approval …
shutterstock_4030507

Insys Therapeutics sees revenue from Subsys at $61-$62 million; shares plunge 21%

April 11, 2016 Business Services, Manufacturing and Production, Sales and Marketing Insys Therapeutics, Stock Price, Subsys, opioids, pain drug

Insys Therapeutics Inc (Nasdaq: INSY) stock plunged nearly 21% Monday after the company said sales for its pain drug will …
mylan_building

Mylan launches new dosages of generic of Novartis hypertension drug in US

April 11, 2016 Manufacturing and Production Mylan, Novartis, generic, high blood pressure, hypertension

Mylan (TASE: MYL) has announced the US launch of new dosages of its generic version of Novartis’s hypertension drug, Lopressor …
The Gateway to Local Adoption Series

Latest content